Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily E Coates

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.
Science Translational Medicine|April 19, 2023
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adultsAlicia T Widge, Amelia R Hofstetter, Katherine V Houser, et al.
The New England Journal of Medicine|August 3, 2022
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent MalariaRichard L Wu, Azza H Idris, Nina M Berkowitz, et al.
The Lancet. Infectious Diseases|August 6, 2023
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trialBetty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, et al.
Lancet (London, England)|January 28, 2023
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trialMelinda J Hamer, Katherine V Houser, Amelia R Hofstetter, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.
Science Translational Medicine|April 19, 2023
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adultsAlicia T Widge, Amelia R Hofstetter, Katherine V Houser, et al.
The New England Journal of Medicine|August 3, 2022
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent MalariaRichard L Wu, Azza H Idris, Nina M Berkowitz, et al.
The Lancet. Infectious Diseases|August 6, 2023
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trialBetty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, et al.
Lancet (London, England)|January 28, 2023
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trialMelinda J Hamer, Katherine V Houser, Amelia R Hofstetter, et al.
Pageof 4